Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: National Cancer Institute (NCI)
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Melanoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01989559 |
NCI-2013-02097 | P1 |
Completed |
Melanoma |
2013-09-01 |
2019-03-20 |
Treatments |
|
NCT00798629 |
MCC-15280 | P1 |
Completed |
Melanoma |
2012-04-01 |
2019-03-18 |
Treatments |
|
NCT00003895 |
NCI-2013-02096 | P2 |
Completed |
Melanoma |
2013-09-01 |
2019-03-21 |
Treatments |
|
NCT00273910 |
06-C-0069 | P2 |
Completed |
Melanoma |
2010-05-01 |
2019-03-22 |
||
NCT00001832 |
99-C-0158 | P2 |
Completed |
Melanoma |
2010-05-01 |
2020-10-26 |
Primary Endpoints|Treatments |
|
NCT00005949 |
NCI-2012-02337 | P2 |
Completed |
Melanoma |
2006-03-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/01/2023 |
PubMed |
ERAP2 supports TCR recognition of three immunotherapy targeted tumor epitopes. |
|
02/01/2020 |
PubMed |
ER-aminopeptidase 1 determines the processing and presentation of an immunotherapy-relevant melanoma epitope. |